Target Search | CytoTargetDB

Only direct cytotoxic targets are shown

Gene

Drug Category

Drug Class

Binding Type

antigen recognition (3404)

other (145)

receptor ligand recognition (192)

Annotation Status

ai (3167)

manual_review_required (574)

Disease Type

CANCER (2959)

NON-CANCER (780)

Tissue

OncoTree Main Type

OncoTree Name

Items per page

Download CSV

Gene	NCT ID	Antigen/Ligand	Binding Type	Drug Name	Drug Category	Drug Class	Drug Description	Drug Mechanism of Action	Target Cytotoxicity Mechanism	Disease	Disease Type	Tissue	OncoTree Main Type	OncoTree Name	Annotation Status
IL2RA	NCT05902416	CD25 (IL-2 receptor alpha)	antigen recognition	Anti-thymocyte globulin	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody that depletes T cells to reduce rejection and GVHD.	Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.	Polyclonal antibodies in ATG bind CD25 (and other T‑cell antigens) on T cells, triggering complement-dependent lysis and Fc-mediated ADCC/phagocytosis to deplete CD25+ T cells.	Myelodysplastic Syndromes	CANCER	Myeloid	Myelodysplastic Syndromes	Myelodysplastic Syndromes	ai
CD28	NCT05902416	CD28	antigen recognition	Anti-thymocyte globulin	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody that depletes T cells to reduce rejection and GVHD.	Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.	Anti-thymocyte globulin binds CD28 on T cells; its Fc activates complement and engages Fcγ-expressing effectors to mediate complement-dependent lysis and ADCC/ADCP, depleting CD28+ cells.	Myelodysplastic Syndromes	CANCER	Myeloid	Myelodysplastic Syndromes	Myelodysplastic Syndromes	ai
PTPRC	NCT05902416	CD45 (PTPRC)	antigen recognition	Anti-thymocyte globulin	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody that depletes T cells to reduce rejection and GVHD.	Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.	ATG binds CD45 on T cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis, leading to lysis and depletion of the target cells.	Myelodysplastic Syndromes	CANCER	Myeloid	Myelodysplastic Syndromes	Myelodysplastic Syndromes	ai
ITGAL	NCT05902416	LFA-1 alpha (CD11a)	antigen recognition	Anti-thymocyte globulin	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody that depletes T cells to reduce rejection and GVHD.	Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.	Anti-thymocyte globulin contains antibodies that bind CD11a (LFA-1 alpha) on T cells and deplete them via complement-dependent lysis and Fc-mediated ADCC/phagocytosis.	Myelodysplastic Syndromes	CANCER	Myeloid	Myelodysplastic Syndromes	Myelodysplastic Syndromes	ai
ITGB2	NCT05902416	Integrin beta-2 (CD18)	antigen recognition	Anti-thymocyte globulin	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody that depletes T cells to reduce rejection and GVHD.	Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.	Polyclonal antibodies bind CD18 (among other T‑cell antigens) and trigger complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, directly depleting CD18+ T cells.	Myelodysplastic Syndromes	CANCER	Myeloid	Myelodysplastic Syndromes	Myelodysplastic Syndromes	ai